Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies
The DOI matches its Crossref record, with a small difference in title or year; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Ulcerative colitis (UC) patients with concomitant primary sclerosing cholangitis (PSC) carry an increased risk of colorectal neoplasia (dysplasia and cancer), whereas the association between PSC and the development of colorectal neoplasia in Crohn's disease (CD) is controversial. A meta-analysis was carried out to compare the risk of this neoplasia in patients with inflammatory bowel disease (IBD) with and without PSC. A systematic research of MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials was performed to identify studies that compared the risk of colorectal neoplasia (dysplasia and cancer) in patients with IBD with and without PSC. Quality assessment was performed using the Newcastle-Ottawa Scale. Pooled odds ratio (OR) was calculated using the random-effects model by STATA 12.0. A total of 16 studies (four cohort studies, 12 case-control studies; nine prospective studies and seven retrospective studies) were selected for further study. These studies included 13 379 IBD patients, of whom 1022 also had PSC. Patients with IBD and PSC were at an increased risk of colorectal dysplasia and cancer compared with patients with IBD alone [OR 3.24; 95% confidence interval (CI): 2.14-4.90]. This increased risk was present even when the risk of colorectal cancer alone was analysed (OR 3.41; 95% CI: 2.13-5.48). Data only from patients with UC showed that PSC was associated with an increased risk for the development of colorectal neoplasia and cancer in patients with UC (OR 2.98; 95% CI: 1.54-5.76) (OR 3.01; 95% CI: 1.44-6.29), but there were high heterogeneity among studies (I=76.9 and 62.8%, respectively). Heterogeneity of the studies was affected by the study design (prospective or retrospective). The OR of colorectal neoplasia was 2.32 (95% CI: 0.70-7.70, P=0.133) and that of cancer was 2.91 (95% CI: 0.84-10.16, P=0.388) for patients with CD and concurrent PSC. Patients with IBD and PSC have a markedly higher risk for the development of colorectal neoplasia than patients with IBD, but not PSC. Stratification by IBD type show that the presence of PSC is associated with an increased risk for the development of colorectal neoplasia in patients with UC; however, there is a nonsignificant association in CD patients. When the risk of colorectal cancer alone is analysed, the conclusion does not change.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“while in a meta-analysis of 16 studies including 1,022 people with PSC-IBD, Zheng et al. reported an odds ratio of 3.24 (95% CI 2.14-4.90) in people with PSC-IBD compared to patients with IBD alone.353,355”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [355]
In the citing paper
“The presence of PSC further increases the risk 3-5-fold compared with that of IBD alone.”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [355]
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Stang, A. (2010) · European Journal of Epidemiology · doi:10.1007/s10654-010-9491-z · Cited by 17,396
The Hazards of Scoring the Quality of Clinical Trials for Meta-analysis
Jüni, P. (1999) · JAMA · doi:10.1001/jama.282.11.1054 · Cited by 1,981
Diagnosis and Management of Primary Sclerosing Cholangitis
Chapman, R., Fevery, J., Kalloo, A., Nagorney, D. M., Boberg, K. M., Shneider, B., & Gores, G. J. (2010) · Hepatology · doi:10.1002/hep.23294 · Cited by 1,224
Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.
Broomé, U., Olsson, R., Lööf, L., Bodemar, G., Hultcrantz, R., Danielsson, A., Prytz, H., Sandberg-Gertzén, H., Wallerstedt, S., & Lindberg, G. (1996) · Gut · doi:10.1136/gut.38.4.610 · Cited by 819
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis
Loftus, E. V., Harewood, G. C., Loftus, C. G., Tremaine, W. J., Harmsen, W. S., Zinsmeister, A. R., Jewell, D. A., & Sandborn, W. J. (2005) · Gut · doi:10.1136/gut.2004.046615 · Cited by 777
Chapman, R. W., Arborgh, B. A., Rhodes, J. M., Summerfield, J. A., Dick, R., Scheuer, P. J., & Sherlock, S. (1980) · Gut · doi:10.1136/gut.21.10.870 · Cited by 732
Soetikno, R. M., Lin, O. S., Heidenreich, P. A., Young, H. S., & Blackstone, M. O. (2002) · Gastrointestinal Endoscopy · doi:10.1067/mge.2002.125367 · Cited by 623
Bile acids as carcinogens in human gastrointestinal cancers
Bernstein, H., Bernstein, C., Payne, C. M., Dvorakova, K., & Garewal, H. (2005) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2004.08.001 · Cited by 611
Research works printed but not linked: 4
- Terg, 2008, Acta Gastroenterol Latinoam, 38, 26
- Shetty, 1999, Am J Gastroenterol, 94, 1643, 10.1111/j.1572-0241.1999.01156.x · doi:10.1111/j.1572-0241.1999.01156.x · Paper page
- Broome, 1995, Hepatology, 22, 1404
- DHaens, 1993, Am J Gastroenterol, 88, 1174
Cited by
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma
Bowlus, C. L., Arrivé, L., Bergquist, A., Deneau, M., Forman, L., Ilyas, S. I., Lunsford, K. E., Martinez, M., Sapisochin, G., Shroff, R., et al. (2023) · Hepatology · doi:10.1002/hep.32771 · Cited by 428
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Wijnands, A. M., de Jong, M. E., Lutgens, M. W. M. D., Hoentjen, F., Elias, S. G., & Oldenburg, B. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.036 · Cited by 240
Palmela, C., Peerani, F., Castaneda, D., Torres, J., & Itzkowitz, S. H. (2018) · Gut and Liver · doi:10.5009/gnl16510 · Cited by 177
British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025
Moran, G. W., Gordon, M., Sinopoulou, V., Radford, S. J., Darie, A.-M., Vuyyuru, S. K., Alrubaiy, L., Arebi, N., Blackwell, J., Butler, T. D., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-334395 · Cited by 169
Metadata
- Authors
- Zheng, H.-H., & Jiang, X.-L.
- Affiliations
- General Hospital of Jinan Military Command (CN)
- Corresponding author
- Jiang, Xue-Liang
- ORCID
- Jiang, Xue-Liang
- Venue
- European Journal of Gastroenterology & Hepatology
- Published
- 2016-04
- Volume
- 28
- Issue
- 4
- Pages
- 383-390
- ISSN
- 0954-691X (ISSN-L)
- OpenAlex
- W2326461674
- Cited by
- 159
- References
- 48
- Citations by year
- 2026: 18 · 2025: 20 · 2024: 10 · 2023: 13 · 2022: 17 · 2021: 21 · 2020: 15 · 2019: 16 · 2018: 13 · 2017: 6 · 2016: 8
- FWCI
- 1.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Gastroenterology & Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
- Keywords
- primary sclerosing cholangitis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, colorectal neoplasia, colorectal cancer, colorectal dysplasia, cancer risk
- MeSH terms
- Colitis, Ulcerative, Crohn Disease, Humans, Risk Factors, Colorectal Neoplasms, Cholangitis, Sclerosing, Risk Assessment, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies. https://app.cochat.ai/papers/10.1097/meg.0000000000000576
- The paper
- Zheng, H.-H., & Jiang, X.-L. (2016). Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies. European Journal of Gastroenterology & Hepatology. https://doi.org/10.1097/meg.0000000000000576
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.